KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Accounts Payables (2017 - 2025)

Novartis Ag's Accounts Payables history spans 9 years, with the latest figure at $4.5 billion for Q4 2025.

  • For Q4 2025, Accounts Payables fell 2.54% year-over-year to $4.5 billion; the TTM value through Dec 2025 reached $4.5 billion, down 2.54%, while the annual FY2025 figure was $4.5 billion, 2.54% down from the prior year.
  • Accounts Payables for Q4 2025 was $4.5 billion at Novartis Ag, down from $4.6 billion in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.6 billion in Q4 2021 and bottomed at $4.5 billion in Q4 2025.
  • The 5-year median for Accounts Payables is $4.9 billion (2023), against an average of $4.9 billion.
  • The largest annual shift saw Accounts Payables grew 2.78% in 2021 before it fell 7.33% in 2022.
  • A 5-year view of Accounts Payables shows it stood at $5.6 billion in 2021, then decreased by 7.33% to $5.1 billion in 2022, then fell by 4.28% to $4.9 billion in 2023, then dropped by 7.19% to $4.6 billion in 2024, then decreased by 2.54% to $4.5 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Accounts Payables are $4.5 billion (Q4 2025), $4.6 billion (Q4 2024), and $4.9 billion (Q4 2023).